MaxCyte Reports Preliminary Q3 Core Revenue Of ~$8.1M, Up 26% YoY; Raises FY26 Revenue Guidance To ~$34M, Core Business Revenue Outlook To ~$28M

Benzinga · 2d ago

MaxCyte, Inc., (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced preliminary revenue for the third quarter ended September 30, 2026 and raised its 2026 revenue guidance.

  • Core business revenue of approximately $8.1 million in the third quarter of 2026, an increase of 26% compared to the third quarter of 2025.

Full Year 2026 Guidance

MaxCyte raises 2026 revenue guidance for core business revenue and SPL Program-related revenue:

  • Full year revenue expected to be approximately $34 million, compared to prior guidance of $30 million to $32 million, consisting of:
    • Core business revenue of approximately $28 million, compared to prior guidance of $25 million to $27 million.
    • SPL Program-related revenue of approximately $6 million for the year, compared to prior guidance of approximately $5 million; SPL Program-related revenue guidance includes both revenue of approximately $4 million from milestone payments and approximately $2 million from commercial royalties.